Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome

Experimental Neurology

Volumn 216, Issue 2, 2009, Pages 321-328

  Ji, Shengbo ^a   Kronenberg, Golo ^a   Balkaya, Mustafa ^a   Färber, Katrin ^b   Gertz, Karen ^a   Kettenmann, Helmut ^b   Endres, Matthias ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Behaviour; Brain ischemia; Inflammation; Long term outcome; Neuroprotection; Pioglitazone; PPAR

Indexed keywords

PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY HEIGHT; BODY WEIGHT; BRAIN ISCHEMIA; CELL COUNT; CELL DEGENERATION; CELL MATURATION; CELL MEMBRANE PERMEABILITY; CELL MOTION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM; EXPERIMENTAL MOUSE; EXPERIMENTAL STUDY; HANGING; IN VITRO STUDY; LEARNING; LONG TERM CARE; MALE; MAZE TEST; MEMORY; MICROGLIA; MIDDLE CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY OCCLUSION; MIGRATION; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION; STEM CELL; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANIMALS, NEWBORN; BROMODEOXYURIDINE; CALCIUM-BINDING PROTEINS; CELL COUNT; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INFARCTION, MIDDLE CEREBRAL ARTERY; MAZE LEARNING; MICE; MICROGLIA; MOTOR ACTIVITY; NEURONS; NEUROPROTECTIVE AGENTS; REACTION TIME; REPERFUSION INJURY; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 62049083791     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.12.007     Document Type: Article

References (57)

1. Bernardo A., Ajmone-Cat M.A., Gasparini L., Ongini E., and Minghetti L. Nuclear receptor peroxisome proliferator-activated receptor-gamma is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen. J. Neurochem. 92 (2005) 895-903
2. Bert B., Fink H., Huston J.P., and Voits M. Fischer 344 and Wistar rats differ in anxiety and habituation but not in water maze performance. Neurobiol. Learn. Mem. 78 (2002) 11-22
3. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., and Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82 (2002) 615-624
4. Cimini A., Benedetti E., Cristiano L., Sebastiani P., D'Amico M.A., D'Angelo B., and Di L.S. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 130 (2005) 325-337
5. Collino M., Aragno M., Mastrocola R., Gallicchio M., Rosa A.C., Dianzani C., Danni O., Thiemermann C., and Fantozzi R. Modulation of oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharmacol. 530 (2006) 70-80
6. Culman J., Zhao Y., Gohlke P., and Herdegen T. PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol. Sci. 28 (2007) 244-249
7. Dehmer T., Heneka M.T., Sastre M., Dichgans J., and Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IkappaBalpha induction and block of NFkappaB and iNOS activation. J. Neurochem. 88 (2004) 494-501
8. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J. Cereb. Blood Flow Metab. 26 (2006) 1465-1478
9. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., and Liao J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 21 (1998) 8880-8885
10. Endres M., Fink K., Zhu J., Stagliano N.E., Bondada V., Geddes J.W., Azuma T., Mattson M.P., Kwiatkowski D.J., and Moskowitz M.A. Neuroprotective effects of gelsolin during murine stroke. J. Clin. Invest. 103 (1999) 347-351
11. Endres M., Meisel A., Biniszkiewicz D., Namura S., Prass K., Ruscher K., Lipski A., Jaenisch R., Moskowitz M.A., and Dirnagl U. DNA methyltransferase contributes to delayed ischemic brain injury. J. Neurosci. 20 (2000) 3175-3181
12. Endres M., Laufs U., Liao J.K., and Moskowitz M.A. Targeting eNOS for stroke protection. Trends Neurosci. 27 (2004) 283-289
13. Endres M., Engelhardt B., Koistinaho J., Lindvall O., Meairs S., Mohr J.P., Planas A., Rothwell N., Schwaninger M., Schwab M.E., Vivien D., Wieloch T., and Dirnagl U. Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc. Dis. 25 (2008) 268-278
14. Feinstein D.L., Galea E., Gavrilyuk V., Brosnan C.F., Whitacre C.C., Dumitrescu-Ozimek L., Landreth G.E., Pershadsingh H.A., Weinberg G., and Heneka M.T. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51 (2002) 694-702
15. Gensch C., Clever Y.P., Werner C., Hanhoun M., Böhm M., and Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 192 (2007) 67-74
16. Gertz K., Priller J., Kronenberg G., Fink K.B., Winter B., Schrock H., Ji S., Milosevic M., Harms C., Bohm M., Dirnagl U., Laufs U., and Endres M. Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow. Circ. Res. 99 (2006) 1132-1140
17. Green A.R., and Shuaib A. Therapeutic strategies for the treatment of stroke. Drug Discov. Today 11 (2006) 681-693
18. Harker K.T., and Whisaw I.Q. Impaired spatial performance in rats with retrosplenial lesions: importance of the spatial problem and the rat strain in identifying lesion effects in a swimming pool. J. Neurosci. 22 (2002) 1155-1165
19. Heneka M.T., Feinstein D.L., Galea E., Gleichmann M., Wüllner U., and Klockgether T. Peroxisome proliferator-activated receptor γ agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol. 100 (1999) 156-168
20. Ieraci A., and Herrera D.G. Nicotinamide protects against ethanol-induced apoptotic neurodegeneration in the developing mouse brain. PLoS Med. 3 (2006) 101
21. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
22. Katchanov J., Harms C., Gertz K., Hauck L., Waeber C., Hirt L., Priller J., von Harsdorf R., Bruck W., Hortnagl H., Dirnagl U., Bhide P.G., and Endres M. Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death. J. Neurosci. 21 (2001) 5045-5053
23. Kiaei M., Kipiani K., Chen J., Calingasan N.Y., and Beal M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 191 (2005) 331-336
24. Kuan C.Y., Schloemer A.J., Lu A., Burns K.A., Weng W.L., Williams M.T., Strauss K.I., Vorhees C.V., Flavell R.A., Davis R.J., Sharp F.R., and Rakic P. Hypoxia-ischemia induces DNA synthesis without cell proliferation in dying neurons in adult rodent brain. J. Neurosci. 24 (2001) 10763-10772
25. Landreth G.E., and Heneka M.T. Landreth and Heneka, Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol. Aging 22 (2001) 937-944
26. Lee Y.B., Yune T.Y., Baik S.Y., Shin Y.H., Du S., Rhim H., Lee E.B., Kim Y.C., Shin M.L., Markelonis G.J., and Oh T.H. Role of tumor necrosis factor-alpha in neuronal and glial apoptosis after spinal cord injury. Exp. Neurol. 166 (2000) 190-195
27. 2 protects brain from ischemia-reperfusion injury. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 481-487
28. Luo Y., Yin W., Signore A.P., Zhang F., Hong Z., Wang S., Graham S.H., and Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. J. Neurochem. 97 (2006) 435-448
29. Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motahashi M., and Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47 (1997) 29-35
30. Matsuura K., Kabuto H., Makino H., and Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods 73 (1997) 45-48
31. McTigue D.M., Tripathi R., Wei P., and Lash A.T. The PPAR gamma agonist pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp. Neurol. 205 (2007) 396-406
32. Moreno S., Farioli-Vecchioli S., and Cerù M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123 (2004) 131-145
33. Niino M., Iwabuchi K., Kikuchi S., Ato M., Morohashi T., Ogata A., Tashiro K., and Onoé K. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J. Neuroimmunol. 116 (2001) 40-48
34. Nolte C., Moller T., Walter T., and Kettenmann H. Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G protein and the rearrangement of the actin cytoskeleton. Neuroscience 73 (1996) 1091-1107
35. Ou Z., Zhao X., Labiche L.A., Strong R., Grotta J.C., Herrmann O., and Aronowski J. Neuronal expression of peroxisome proliferator-activated receptor-γ (PPARγ) and 15d-prostaglandin J2-mediated protection of brain after experimental ischemia in rat. Brain Res. 1096 (2006) 196-203
36. Pereira M.P., Hurtado O., Cárdenas A., Alonso-Escolano D., Boscá L., Vivancos J., Nombela F., Leza J.C., Lorenzo P., Lizasoain I., and Moro M.A. The nonthiazolidinedione PPARγ agonist L-796,449 is neuroprotective in experimental stroke. J. Neuropathol. Exp. Neurol. 64 (2005) 797-805
37. Pineau I., and Lacroix S. Proinflammatory cytokine synthesis in the injured mouse spinal cord: multiphasic expression pattern and identification of the cell types involved. J. Comp. Neurol. 500 (2007) 267-285
38. Prinz M., Kann O., Draheim H.J., Schumann R.R., Kettenmann H., Weber J.R., and Hanisch U.K. Microglial activation by components of gram-positive and -negative bacteria: distinct and common routes to the induction of ion channels and cytokines. J. Neuropathol. Exp. Neurol. 58 (1999) 1078-1089
39. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
40. Roth A.D., Leisewitz A.V., Jung J.E., Cassina P., Barbeito L., Inestrosa N.C., and Bronfman M. PPAR gamma activators induce growth arrest and process extension in B12 oligodendrocyte-like cells and terminal differentiation of cultured oligodendrocytes. J. Neurosci. Res. 72 (2003) 425-435
41. Roses A.D., Saunders A.M., Huang Y., Strum J., Weisgraber K.H., and Mahley R.W. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J. 7 (2007) 10-28
42. Schutz B., Reimann J., Dumitrescu-Ozimek L., Kappes-Horn K., Landreth G.E., Schürmann B., Zimmer A., and Heneka M.T. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25 (2005) 7805-7812
43. Semmler A., Okulla T., Sastre M., Dumitrescu-Ozimek L., and Heneka M.T. Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. J. Chem. Neuroanat. 30 (2005) 144-157
44. Shimazu T., Inoue I., Araki N., Asano Y., Sawada M., Furuya D., Nagoya H., and Greenberg J.H. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36 (2005) 353-359
45. Streit W.J., Semple-Rowland S.L., Hurley S.D., Miller R.C., Popovich P.G., and Stokes B.T. Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp. Neurol. 152 (1998) 74-87
46. Sundararajan S., Gamboa J.L., Victor N.A., Wander E.W., Lust W.D., and Landreth G.E. Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130 (2005) 685-696
47. Swanson R.A., Morton M.T., and Tsao-Wu G. A semiautomated method for measuring brain infarct volume. J. Cereb. Blood Flow Metab. 10 (1990) 290-293
48. Victor N.A., Wanderi E.W., Gamboa J., Zhao X., Aronowski J., Deininger K., Lust W.D., Landreth G.E., and Sundararajan S. Altered PPARγ expression and activation after transient focal ischemia in rats. Eur. J. Neurosci. 24 (2006) 1653-1663
49. Wang C.X., Nuttin B., Heremans H., Dom R., and Gybels J. Production of tumor necrosis factor in spinal cord following traumatic injury in rats. J. Neuroimmunol. 69 (1996) 151-156
50. Wilcox R., Bousser M.G., Betteridge D.J., Schernthaner G., Pirags V., Kupfer S., and Dormandy J. PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38 (2007) 865-873
51. Winter B., Bert B., Fink H., Dirnagl U., and Endres M. Dysexecutive syndrome after mild cerebral ischemia? Mice learn normally but have deficits in strategy switching. Stroke 35 (2004) 191-195
52. Winter B., Juckel G., Viktorov I., Katchanov J., Gietz A., Sohr R., Balkaya M., Hörtnagl H., and Endres M. Anxious and hyperactive phenotype following brief ischemic episodes in mice. Biol. Psychiatry 15 (2005) 1166-1175
53. Wosikowski K., Küng W., Hasmann M., Löser R., and Eppenberger U. Inhibition of growth-factor-activated proliferation by anti-estrogens and effects on early gene expression of MCF-7 cells. Int. J. Cancer. 53 (1993) 290-297
54. Zhao Y., Patzer A., Gohlke P., Herdegen T., and Culman J. The intracerebral application of the PPARγ-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur. J. Neurosci. 22 (2005) 278-282
55. Zhao, X., Ou, Z., Grotta, J.C., Waxham, N., Aronowski, J., 2006a. Peroxisome-proliferator-activated receptor-γ (PPARγ) activation protects neurons from NMDA excitotoxicity. Brain Res. 1073-1074, 460-469.
56. Zhao X., Zhang Y., Strong R., Grotta J.C., and Aronowski J. 15d-Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J. Cereb. Blood Flow Metab. 26 (2006) 811-820
57. Zhao Y., Patzer A., Herdegen T., Gohlke P., and Culman J. Activation of cerebral peroxisome proliferator-activated receptors γ promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J. 20 (2006) 1162-1175